Doctor Nicola Maurea

Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

Member of:

Prof. Nicola Maurea was born in Naples on 30.04.1961. In 1985 he received a degree in Medicine and Surgery from the University of Naples. In 1988 he obtained the Specialization in Cardiovascular Diseases at the University of Naples. In 1993 he obtained the Specialization in Internal Medicine at the University of Naples. In 1995 he attended the Echocardiography Laboratory of Duke University Medical Center in Boston, USA. In 1996 he attended the Echocardiography laboratory of the Thorax Center in Rotterdam, Holland. Since January 2005 he has been Director of the Division of Cardiology of the National Cancer Institute IRCCS Pascale Foundation of Naples. Since January 2008 he has been Director of the Departmental Emergency Area INT Pascale Foundation. He is the author of several international publications. His area of experience is in the field of clinical and translational cardioncology.

Presentations Articles

GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences

Event: Heart Failure 2025

Topic: Cardio-Oncology

Session: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies

Access

Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways

Event: Heart Failure 2025

Topic: Cardio-Oncology

Session: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies

Access

GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

Event: Heart Failure 2025

Topic: Cardio-Oncology

Session: Cardio-oncology - diagnostic and therapeutic advances

Access

The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

Event: Heart Failure 2025

Topic: Cardio-Oncology

Session: Cardio-oncology - diagnostic and therapeutic advances

Access

Dapagliflozin improves ejection fraction, radial/longitudinal strain and reduces systemic H-FABP and pro-inflammatory cytokines in models of dororubicin/trastuzumab induced cardiotoxicity

Event: EuroEcho-Imaging 2024

Topic: Myocardial Disease

Session: Challenges in cardio oncology

Access

The SGLT-2 inhibitor empagliflozin improves myocardial strain,ejection fraction, reduces pro-inflammatory cytokines and H-FABP/troponin in models of anthracyline-induced cardiotoxicity

Event: EuroEcho-Imaging 2024

Topic: Myocardial Disease

Session: Imaging in cardio-oncology

Access

Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: How to improve prognosis in cardio-oncology

Access

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: Cardiovascular disease in special populations - cardio-oncology (1)

Access

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

Event: ESC Congress 2023

Topic: Cardio-Oncology

Session: Cardiotoxicity: mechanisms, biomarkers, and treatment

Access

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Event: ESC Congress 2023

Topic: Cardio-Oncology

Session: Cardiotoxicity: mechanisms, biomarkers, and treatment

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Nicola Maurea

Biography

Contributor content

GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences

Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways

GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

Dapagliflozin improves ejection fraction, radial/longitudinal strain and reduces systemic H-FABP and pro-inflammatory cytokines in models of dororubicin/trastuzumab induced cardiotoxicity

The SGLT-2 inhibitor empagliflozin improves myocardial strain,ejection fraction, reduces pro-inflammatory cytokines and H-FABP/troponin in models of anthracyline-induced cardiotoxicity

Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

ESC 365 is supported by

Doctor Nicola Maurea Follow

Biography

Contributor content

GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences

Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways

GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

Dapagliflozin improves ejection fraction, radial/longitudinal strain and reduces systemic H-FABP and pro-inflammatory cytokines in models of dororubicin/trastuzumab induced cardiotoxicity

The SGLT-2 inhibitor empagliflozin improves myocardial strain,ejection fraction, reduces pro-inflammatory cytokines and H-FABP/troponin in models of anthracyline-induced cardiotoxicity

Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

ESC 365 is supported by

Doctor Nicola Maurea